Detail akcie Fortress Biotch Rg online

Business Summary: Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13R?2 CAR T Cell Program for Glioblastoma), and others.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Fortress Biotech Inc revenues increased 11% to $47.2M. Net income applicable to common stockholders totaled $4.3M vs. loss of $46.2M. Revenues reflect Journey segment increase of 8% to $45.8M. Net Income reflects Mustang segment loss decrease of 88% to $1.8M, Journey segment loss decrease of 51% to $7.8M, Avenue segment loss decrease of 76% to $2.3M.